Abstract
Hydroxamic acids are a promising class of chemical compounds with proven antitumor potential, primarily due to their ability to inhibit the activity of histone deacetylase enzymes. The analysis of modern experimental data shows a wide range of biological activities of hydroxamic acids, which make them equally worthy candidates for the fight against neuropathologies. A characteristic feature of hydroxamic acids is their ability to act simultaneously on several promising molecular targets for the correction of both neuropathologies and oncological diseases, thereby exhibiting multifunctionality. This review discusses the effect of hydroxamic acids on key parts of cancer and neurodegenerative disorders' pathogenesis. Pathological changes in the processes associated with oxidative stress, the functioning of mitochondria, and the activity of metal enzymes of the class of histone deacetylases, as the main links in the epigenetic regulation of pathological conditions, are such molecular targets.
Keywords: Hydroxamic acids, cancer, neurodegenerative diseases, oxidative stress, mitochondria, histone deacetylase.
Current Medicinal Chemistry
Title:The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Volume: 28 Issue: 39
Author(s): Margarita E. Neganova, Sergey G. Klochkov, Yulia R. Aleksandrova and Gjumrakch Aliev*
Affiliation:
- Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka,Russian Federation
Keywords: Hydroxamic acids, cancer, neurodegenerative diseases, oxidative stress, mitochondria, histone deacetylase.
Abstract: Hydroxamic acids are a promising class of chemical compounds with proven antitumor potential, primarily due to their ability to inhibit the activity of histone deacetylase enzymes. The analysis of modern experimental data shows a wide range of biological activities of hydroxamic acids, which make them equally worthy candidates for the fight against neuropathologies. A characteristic feature of hydroxamic acids is their ability to act simultaneously on several promising molecular targets for the correction of both neuropathologies and oncological diseases, thereby exhibiting multifunctionality. This review discusses the effect of hydroxamic acids on key parts of cancer and neurodegenerative disorders' pathogenesis. Pathological changes in the processes associated with oxidative stress, the functioning of mitochondria, and the activity of metal enzymes of the class of histone deacetylases, as the main links in the epigenetic regulation of pathological conditions, are such molecular targets.
Export Options
About this article
Cite this article as:
Neganova E. Margarita , Klochkov G. Sergey , Aleksandrova R. Yulia and Aliev Gjumrakch*, The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents, Current Medicinal Chemistry 2021; 28 (39) . https://dx.doi.org/10.2174/0929867328666201218123154
DOI https://dx.doi.org/10.2174/0929867328666201218123154 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Promising Therapies in Sickle Cell Disease
Cardiovascular & Hematological Disorders-Drug Targets TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry Antiestrogenic Therapies in Solid Cancers and Multiple Myeloma
Current Molecular Medicine Recent Developments in the Discovery of Selective Glucocorticoid Receptor Modulators (SGRMs)
Current Topics in Medicinal Chemistry LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews Editorial (The Ubiquitin Proteasome System as a Source of Drug Targets for Cancer Therapy)
Current Pharmaceutical Design Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry The Tumor Suppressor p53 Regulates c-Maf and Prox-1 to Control Lens Differentiation
Current Molecular Medicine